Patented technology
   The Company’s technology utilizes passive enhancement chemistry in a patented, dual
delivery system for the use of estrogen and progestin in contraception.
   Active Adhesive System designed to deliver estrogen and progestin combination over the 7-day period at doses needed for contraception.
   U.S. 7,045,145
   Intermediate wet formulation (manufacturing patent)
   U.S. 7,384,650
   Dry formulation – provides ranges for four active enhancers used to deliver estrogen and progestin for contraception
   (Patent pending)
   PK claims (CMAX and AUC) for ethinyl estradiol and levonorgestrel
   System claims with expanded scope
   Unique 7-day/3-week delivery curve
   Peripheral Adhesive System prevents evaporation, maintains stability and improves adhesion and
comfort
   (Patent pending)
   Peripheral adhesive and release liner to prevent evaporation of substances and maintain product stability
   (Patent pending)
   Alternative design using ultrasonic welding of backing layer to release liner to prevent evaporation of substances
   Unique transdermal dosing regimens for next generation products
   Reflects patient preference on controlling frequency/duration of menses and the benefits of shortened hormonal free intervals
   Applications to other therapeutic areas and substances